Key Data Presented at the 2017 Hematology Annual Meeting - prIME Oncology
prIME Clinical Update
prIME Clinical Update

Key Data Presented at the 2017 Hematology Annual Meeting

Critical Analysis and Practical Application

Not a member of My prIME? Join now for instant access.

View CME-certified expert discussions to get the latest updates in hematologic malignancies released at the 2017 Hematology Annual Meeting in Atlanta. This activity includes critical analysis of the clinical trial data, and discussion on how these data may or should impact clinical practice.

Interactive Presentation

Interactive Presentation

CME

CME

1.75 AMA PRA Category 1 Credits™

Release Date

Release Date

Dec 15, 2017

Expiration Date

Dec 15, 2018

Acute Myeloid Leukemia

Featured Experts

  • Jorge Cortes, MD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
  • Francesco Lo Coco, MD, University Tor Vergata, Rome, Italy

Featured Topics

Abstract #29: Early detection of WT1 minimal residual disease predicts outcome in acute myeloid leukemia and identify patients with high risk of relapse independently of allogeneic stem cell transplantation

Abstract #145: An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations

Abstract #638: Enasidenib monotherapy is effective and well-tolerated in patients with previously untreated mutant-IDH2 (mIDH2) acute myeloid leukemia (AML)

Abstract #639: Mutant isocitrate dehydrogenase (mIDH) inhibitors, enasidenib or ivosidenib, in combination with azacitidine (AZA): Preliminary results of a phase 1b/2 study in patients with newly diagnosed acute myeloid leukemia (AML)

Abstract #726: Ivosidenib or enasidenib combined with standard induction chemotherapy is well tolerated and active in patients with newly diagnosed AML with an IDH1 or IDH2 mutation: Initial results from a phase 1 trial

Abstract #1299: Continuing enasidenib treatment for patients with mutant-IDH2 (mIDH2) relapsed or refractory acute myeloid leukemia (R/R AML) with stable disease may result in improved survival and responses over time

Abstract #1332: A phase II study of midostaurin and 5-azacitidine for elderly patients with acute myeloid leukemia

Abstract #2580: The addition of midostaurin to standard chemotherapy decreases cumulative incidence of relapse (CIR) in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603 / RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations

Abstract #LBA-5: Prospective molecular MRD detection by NGS: A powerful independent predictor for relapse and survival in adults with newly diagnosed AML

CAR T-Cell Therapy

Featured Expert

  • David Miklos, MD, PhD, Stanford University, Stanford, California, United States

Featured Topics

Abstract #577: Primary analysis of Juliet: A global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma

Abstract #578: Long-term follow-up ZUMA-1: A pivotal trial of axicabtagene ciloleucel (Axi-Cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)

Abstract #579: A comparison of one year outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with refractory, aggressive non-Hodgkin lymphoma (NHL)

Abstract #581: High durable CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): Defined composition allows for dose-finding and definition of pivotal cohort

Abstract #1547: Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL)

Abstract #2826: Phase 1 results from ZUMA-6: Axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL)

Chronic Lymphocyctic Leukemia

Featured Experts

  • Jan Burger, MD, PhD, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
  • Jacqueline Barrientos, MD, MS, Northwell Health, Lake Success, New York, United States

Featured Topics

Abstract #427: Randomized trial of ibrutinib versus ibrutinib plus rituximab (Ib+R) in patients with chronic lymphocytic leukemia (CLL)

Abstract #432: Acalabrutinib with obinutuzumab in relapsed/refractory and treatment-naive patients with chronic lymphocytic leukemia: The phase 1b/2 ACE-CL-003 study

Abstract #498: Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: Updated results from the phase 1/2 ACE-CL-001 study

Abstract #832: Evaluating the efficacy, safety, and dose dependent activities of entospletinib in patients with chronic lymphocytic leukemia

Abstract #833: Safety and efficacy of the combination of ibrutinib and nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia

Abstract #LBA-2: Venetoclax plus rituximab is superior to bendamustine plus rituximab in patients with relapsed/ refractory chronic lymphocytic leukemia – Results from pre-planned interim analysis of the randomized phase 3 Murano study

Cutaneous T-Cell Lymphoma

Featured Experts

  • Miles Prince, MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACD, Peter MacCallum Cancer Center, Victoria, Australia
  • Alison Moskowitz, MD, Memorial Sloan Cancer Center, New York, New York, United States

Featured Topics

Abstract #817: Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL): Results from the phase III MAVORIC study

Abstract #819: In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-δ,γ inhibitor, in combination with romidepsin or bortezomib in relapsed/refractory T-cell lymphoma

Abstract #1509: Updated Analyses of the international, open-label, randomized, phase 3 Alcanza study: Longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL)

Mantle Cell Lymphoma

Featured Expert

  • Simon Rule, MPhil, FRCP, FRCPA, FRCPath, University of Plymouth, Plymouth, United Kingdom

Featured Topics

Abstract #151: Median 3.5-year follow-up of ibrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: A pooled analysis

Abstract #152: Safety and activity of the highly specific btk inhibitor bgb-3111 in patients with indolent and aggressive non Hodgkin’s lymphoma

Abstract #153: Rituximab maintenance after first-line immunochemotherapy in mantle cell lymphoma: Long-term follow-up of the randomized European MCL Elderly trial

Abstract #154: Initial treatment with lenalidomide plus rituximab for mantle cell lymphoma: 5-year follow-up and correlative analysis from a multi-center phase ii study

Abstract #155: Efficacy and safety of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma in the phase 2 ACE-LY-004 study

Abstract #2785: Phase Ib-II study of Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, w/ lenalidomide and rituximab in relapsed / refractory mantle cell lymphoma

Multiple Myeloma

Featured Experts

  • Meletios Dimopoulos, MD, University of Athens, Athens, Greece
  • Shaji Kumar, MD, Mayo Clinic, Rochester, Minnesota, United States

Featured Topics

Newly Diagnosed MM

Abstract #400: Response-adapted lenalidomide maintenance in newly diagnosed, transplant-eligible multiple myeloma: Results from the multicenter phase III GMMG-MM5 trial

Abstract #438: Two dose series of high-dose influenza vaccine is associated with longer duration of serologic immunity in patients with plasma cell disorders

Abstract #902: Efficacy and safety of long-term ixazomib maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) not undergoing transplant: An integrated analysis of four phase 1/2 studies

Abstract #903: Tackling EArly Morbidity and Mortality in Myeloma (TEAMM): Assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections in 977 patients

Abstract #LBA-4: Phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) in newly diagnosed multiple myeloma (NDMM) patients (pts) Ineligible for transplant (ALCYONE)


R/R MM

Abstract #739: Daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Updated efficacy and safety analysis of Pollux

Abstract #740: Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: Updated results from a multicenter study of bb2121 anti-BCMA CAR T cell therapy

Abstract #741: Deep and durable responses in patients (pts) with relapsed/refractory multiple myeloma (MM) treated with monotherapy GSK2857916, an antibody drug conjugate against B-cell maturation antigen (BCMA): Preliminary results from part 2 of study BMA117159

Abstract #743: Overall survival (OS) of patients with relapsed/refractory multiple myeloma (RRMM) treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd): Final Analysis from the randomized phase 3 Aspire trial

Abstract #837: A multicenter open label phase II study of pomalidomide, cyclophosphamide and dexamethasone in relapse multiple myeloma patients initially treated with lenalidomide, bortezomib and dexamethasone

Abstract #1818: Duration of therapy (DOT) and time to next therapy (TTNT) of bortezomib, carfilzomib and ixazomib combinations with lenalidomide/dexamethasone (VRd, KRd, IRd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Clinical practice in the United States vs clinical trial experience

Abstract #1886: Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs dexamethasone alone in patients with relapsed/refractory multiple myeloma

Non-Hodgkin Lymphoma

Featured Experts

  • Jonathon B. Cohen, MD, MS, Emory University, Winship Cancer Center, Atlanta, Georgia, United States
  • Loretta Nastoupil, MD, The University of Texas , MD Anderson Cancer Center, Houston, Texas, United States

Featured Topics

Abstract #187: Encouraging early results from the first in-human clinical trial of Adct-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory B-cell lineage non-Hodgkin lymphoma

Abstract #189: Lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma: Final phase I/II results

Abstract #192: A phase I, open-label, multicenter trial of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma, grade 3B follicular lymphoma, or transformed lymphoma

Abstract #197: Clinical significance of PD-1 and PD-L1 expression and ongoing interaction in the tumor microenvironment in diffuse large B cell lymphoma (DLBCL) treated with R-CHOP

Abstract #577: Primary analysis of Juliet: A global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma

Abstract #578: Long-term follow-up ZUMA-1: A pivotal trial of axicabtagene ciloleucel (Axi-Cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)

Abstract #579: A comparison of one year outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in patients with refractory, aggressive non-Hodgkin lymphoma (NHL)

Abstract #581: High durable CR rates in relapsed/refractory (R/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (TRANSCEND NHL 001): Defined composition allows for dose-finding and definition of pivotal cohort

Abstract #1547: Preliminary results of prophylactic tocilizumab after axicabtagene ciloleucel (KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL)

  • Jacqueline Barrientos, MD, MSNorthwell Health
    Lake Success, New York, United States
  • Jan Burger, MD, PhDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Jonathon B. Cohen, MD, MSEmory University
    Winship Cancer Center
    Atlanta, Georgia, United States
  • Jorge Cortes, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Meletios Dimopoulos, MDUniversity of Athens
    Athens, Greece
  • Shaji Kumar, MDMayo Clinic
    Rochester, Minnesota, United States
  • Francesco Lo Coco, MDUniversity Tor Vergata
    Rome, Italy
  • David Miklos, MD, PhDStanford University
    Stanford, California, United States
  • Alison Moskowitz, MDMemorial Sloan Cancer Center
    New York, New York, United States
  • Loretta Nastoupil, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Miles Prince, MBBS (Hons), MD, FRACP, FRCPA, AFRACMA, MACDPeter MacCallum Cancer Center
    Victoria, Australia
  • Simon Rule, MPhil, FRCP, FRCPA, FRCPathUniversity of Plymouth
    Plymouth, United Kingdom

This educational activity is designed to meet the needs of practicing hematologists, oncologists, oncology nurses, researchers, and other healthcare professionals involved and/or interested in the management of patients with hematologic malignancies and the consequences of these diseases.

After successful completion of this educational activity, participants should be able to:

  • Compare new and emerging treatment strategies with established options

This educational activity is supported by grants from AstraZeneca, Celgene Corporation, Gilead Sciences, Inc., Pharmacyclics, LLC, and Takeda Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Key Data Presented at the 2017 Hematology Annual Meeting - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each module may provide the following credits:

  • Acute Myeloid Leukemia: 0.25
  • CAR-T Cell Therapy: 0.25
  • Chronic Lymphocyctic Leukemia: 0.25
  • Cutaneous T Cell: 0.25
  • Mantle Cell Lymphoma: 0.25
  • Multiple Myeloma: 0.25
  • Non-Hodgkin Lymphoma: 0.25

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Barrientos has disclosed that she has received consulting fees from AbbVie and Gilead. She has also received fees for membership on advisory committee or review panel from Pharmacyclics. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Burger has disclosed that he has received fees for membership on advisory committees or review panels from Gilead, Janssen, and Pharmacyclics. He has also received fees for speaking and teaching from Janssen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Cohen has disclosed that he has received consulting fees from AbbVie, Celgene Corporation, Genentech, and Janssen. He has also received research funding from Bristol-Myers Squibb, Novartis Oncology, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Cortes has disclosed that he has received consulting fees from and performed contracted research for Astellas, Bristol-Myers Squibb, Daiichi, Immunogen, Novartis, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Dimopoulos has disclosed that he has received consulting fees from Amgen, Celgene Corporation, Janssen Pharmaceuticals, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kumar has disclosed that he has been an independent contractor for AbbVie, Bristol-Myers Squibb, Celgene Corporation, Janssen Pharmaceuticals, Novartis Oncology, Roche, Sanofi, and Takeda. He has membership on advisory committees or review panels from AbbVie, Celgene Corporation, Janssen Pharmaceuticals, Oncopeptides, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lo Coco has disclosed that he has received fees for membership on advisory boards from Novartis Oncology and Teva. He has also received consulting fees from Orsenix. He has received honoraria for promotional speaker’s bureaus from Lundbeck, Novartis Oncology and Teva. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Miklos has disclosed that he has received consulting fees from Kite Pharma, Inc., Novartis Oncology, and Pfizer. He has also disclosed independent contracting for Kite Pharma, Inc., Novartis Oncology, and Pharmacyclics. He has received fees for membership on advisory committee or review panel from Adaptive Biotech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Moskowitz has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Nastoupil has disclosed that she has performed contracted research for or received research support from AbbVie, Celgene Corporation, Genentech, Janssen, and TG. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Prince has disclosed that he has received fees for membership on advisory committee and speaking and teaching from Takeda/Millennium. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Rule has disclosed that he has received consulting fees from AstraZeneca, Celgene Corporation, Gilead, Janssen, Pharmacyclics, and Roche. He has also received fees for promotional speaker’s bureau and independent contracting from Janssen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Elizabeth Cameron, PhD (clinical content reviewer/planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.